The central risk is sequencing, not pure science. AST likely has a real product, but the equity outcome depends on synchronizing launches,
gateway readiness, regulatory approvals, and carrier commercialization before pricing pressure or financing needs dilute the payoff. If carriers price the service as insurance rather than essential utility, the business can scale operationally while equity returns still disappoint.